Skin and Joints Podcast

🎙️ If They Get There, Do They Stay There? A 140-Week AD Data Dive — Part 1 of a 2-Part Double Header Guests: Dr. Marissa Joseph and Dr. Fiona LovegroveLocation: 📍 AAD 2026 We came to Denver for AAD 2026, adjusted to the altitude, caught our breath — barely — and dove straight into the data. In Part 1 of this two-part atopic dermatitis double header, Dr. Marissa Joseph and Dr. Fiona Lovegrove join us live from the Mile High City to break down fresh new clinical data in moderate-to-severe atopic dermatitis, with a focus on long-term maintenance of stringent patient-reported outcomes with upadacitinib from the Measure Up 1 and Measure Up 2 studies. Because patients do not walk into clinic asking if their EASI score improved by 70%.They ask: “Will I sleep?”“Will the itch stop?”“Can I focus at work or school?”“Can I stop thinking about my eczema every single day?” Our conversation gets into the so what behind the numbers —what this data implies for your real world patient decisions, why durability matters, why week 16 response may help guide long-term expectations, and why patient-reported outcomes are moving from nice-to-have to true treatment targets in atopic dermatitis. We also explore the challenge of measuring multiple domains in practice, and why aiming high does not mean treating partial responders as failures. How do our experts frame better sleep, less itch, and fewer daily disease interruptions for these partial responders? Think of this as your compact AAD post-game analysis — but instead of Shaq and the scoreboard, we’re breaking down itch, sleep, emotional burden, dose optimization, and the future of treat-to-target AD care. Learning Objectives:By the end of this episode, listeners will be able to: Describe the clinical relevance of long-term patient-reported outcome data in moderate-to-severe atopic dermatitis. Discuss how itch, sleep, emotional burden, and daily functioning can inform treatment success beyond skin clearance alone. Interpret the significance of sustained responses from week 16 through longer-term follow-up in the Measure Up 1 and 2 studies. Identify practical considerations and limitations when incorporating stringent PRO targets into real-world dermatology practice. Apply key insights from AAD 2026 data to therapeutic decision making, patient counselling, expectation-setting, and shared decision-making in AD care. Skin and Joints Podcast — where we bring the science, the clinical translation, and just enough altitude-related commentary to keep things interesting. Part 2 is already warming up in the bullpen. REFERENCES: Long-Term Maintenance of Stringent Patient-Reported Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Measure Up 1 and 2 Phase 3 Studies #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #Upadacitinib #MeasureUp #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor Supported by an IME Grant from ABBVIE..

PART2-Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025 Guests: Dr. Chloe Ward & Dr. Natalie Cunningham Location: 📍 EADV 2025, Paris 🇫🇷 From café chatter to late-breaker abstracts, this fresh field report stitches together breaking new data and what matters for acne care today. Our two Canadian derm Faculty dynamos, Dr. Chloe Ward and Dr. Natalie Cunningham, join us live from EADV 2025 to decode acne in the TikTok age. We swap “Dr. Google” for real talk on psychosocial fallout (filters, FOMO, and 4 a.m. routines), sanity-check the diet myths, and map where AI actually helps in assessment—think consistent severity tracking and smarter primary-care triage—without replacing clinical eyes (especially in richer skin tones). Drs. Ward and Cunningham unpack multimodal regimens patients can actually tolerate, topical androgen-receptor blockade at the sebaceous unit, and smarter maintenance so scars don’t steal the show. We dig into pigment beyond classic PIH (hello, primary melanogenesis), when energy devices earn a seat (including a 1726-nm sebaceous-targeting laser), why most at-home red light is a detour, and the rare moments biologics enter the chat for overlap/refractory cases. Throughout: practical pearls and fresh evidence Learning Objectives After this episode, participants will be able to: 🧠 Assess psychosocial burden in acne (sleep 💤, stress 😰, social media behaviors 📱) and integrate into severity and treatment decisions 🩺. 🥗 Debunk prevalent myths (“diet cures acne” ❌) with balanced, evidence-based counseling 📖 that acknowledges diet/stress/hormones as contributors, not sole causes ⚖️. 🧴 Design patient-centered, multimodal regimens that optimize efficacy ✅ and tolerability 🤝—leveraging combination therapy 🔗. 🧬 Explain mechanisms (incl. topical androgen-receptor blockade at the sebaceous gland) and position them in stepwise care from induction 🚀 to maintenance 🔁. 🎨 Differentiate pigment pathways (PIH vs. emerging primary melanogenesis) and tailor strategies for all skin tones 🌈 with rigorous photoprotection 🧢🕶️. 🤖 Use AI judiciously for documentation 📝 and triage 🏥; recognize limitations in diverse skin tones 🌍 and keep the patient’s lived experience central ❤️. 🛡️ Prevent scars proactively by identifying scar-risk patients early ⏱️ and escalating appropriately (e.g., isotretinoin candidacy) 🎯. 🔦 Outline the role of energy-based devices (including the 1726-nm sebaceous-targeting laser) in reducing inflammation 🔥, erythema 🌺, and remodeling 🧱—and why most at-home red-light devices fall short 🚫🔴. 🧬 Spot the edge cases where biologics or overlap-syndrome thinking may be appropriate 🧩, and outline key research gaps to watch 🔭 (hormonal pathways, AI validation, long-term maintenance). Perfect for Dermatologists, primary-care clinicians, pharmacists, nurses, and any HCP who fields “I saw this on TikTok…” and wants practical, patient-first ways to translate Paris-level science into Monday-morning care. Supported by an IME Grant from SUN Pharma.

Paris Pop-Up: Hands Down the Most Fun You’ll Have Learning About Chronic Hand Eczema Late Breaker Edition Chronic Hand Eczema in Focus: DELTA-Teen efficacy & pooled safety of topical pan-JAK Episode Tasting Menu 🍽️: Jet-lag ✈️, steak-frites , and NEW science : we unpack fresh adolescent data for a topical pan-JAK cream in chronic hand eczema (CHE) and a pooled safety package that’s so uneventful it’s…beautiful 😌. (Melinda’s words: “Boring is good.”) Fresh from EADV Paris 🗼🇫🇷, the team breaks down two late-breaking updates on CHE: 1. DELTA-Teen — a randomized (3:1) 16-week trial of a topical pan-JAK inhibitor (delgocitinib cream) in adolescents (12–17) with moderate–severe CHE. 📊 2. Pooled safety analysis across five trials (Phase 2b/3; 16-week regular use + up to 52-week as-needed). 🛡️📈 What’s on the tasting menu : • EADV in Paris — highlights with a dash of Melinda’s Paris story 🥐📸 • Current adolescent CHE care — steroid limits & non-steroidal gaps • DELTA-Teen unpacked — design, endpoints, results, onset, adherence impact • Safety deep-dive — pooled 5-trial analysis, 52-week PRN, counseling talking points • Practice pearls — payer metrics (IGA-CHE), cross-setting messaging, fast-tracking from primary care • Wrap — off-label nuance, what to tell parents/teens, what to watch for next We dive into where a non-steroidal topical JAK can fit for adolescents—an area with gaps given steroid hesitancy and tolerability issues with other non-steroidals 🧩. Plus, a practical workflow map 🗺️: primary care triage → dermatology fast-track → pharmacy counseling (steroid fears, adherence benefits from rapid itch relief) → documentation (expect IGA-CHE to be required by payers). Importantly, efficacy signals span CHE subtypes (atopic, irritant, allergic) ✅—supporting broad real-world relevance 🌍. Learning objectives 🎯: 1. Describe the DELTA-Teen trial design for adolescent CHE, including primary (IGA-CHE TS) and key secondary endpoints (HECSI-90, HESD itch/pain). 2. Interpret week-16 efficacy results and differentiate early patient-reported benefits from statistical-significance timing (e.g., week-12 separation)—and weave this into adherence counseling ⏳. 3. Summarize pooled safety across five trials (16-week regular use + up to 52-week PRN): common AEs, no increased AE rates vs vehicle, and implications of minimal systemic absorption & no boxed warning for topical delgocitinib 🛡️📉. 4. Identify gaps in adolescent CHE management (steroid limitations, tolerability of other non-steroidals) and position topical pan-JAK inhibitors appropriately—acknowledging off-label use where applicable 🧭. 5. Apply a care-pathway playbook (primary care → dermatology → pharmacy counseling → payer documentation) and document outcomes likely required for access (e.g., IGA-CHE scoring) across CHE subtypes 📋✅. Practical pearls (AKA Clinic Cheat Codes) : • Expect early itch relief that can boost adherence; set expectations about week-12 statistical separation ⏱️🙌. • Use IGA-CHE in documentation; keep HECSI-90/HESD in mind for research/quality initiatives 📝🔍. • Safety talking points: AEs comparable to vehicle; long-term PRN data up to 52 weeks; discuss the no boxed warning context vs class concerns 🛡️🗣️. • Reinforce steroid-sparing options to address teen/parent anxieties about skin thinning 🧴. • Subtype-agnostic efficacy supports practical use while you sort mixed etiologies 🧪🔄. — Notes ⚠️🗒️: Adolescent use discussed here reflects off-label prescribing in many regions pending any label extension. Always consult local product labeling and guidance. ________________________________________ #SkinAndJointsPodcast #ChronicHandEczema #CHE #EADV2025 #Paris #Dermatology #DELTATeen #Delgocitinib #JAKInhibitor #TopicalJAK #AdolescentDerm #PediatricDerm #ItchRelief #SteroidSparing #ClinicalTrials #RealWorldEvidence #IGACHE #HECSI90 #HESD #PracticePearls #DermPharmacy #MedEd #HCPs #EvidenceBasedDerm SUPPORTED BY AN IME GRANT FROM LEO PHARMA ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology) Toronto, ON Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases. 📻www.skinandjoints.ca ✉️info@skinandjoints.ca

🎙️ Our PsO Playbook: Brothers on the Fairway, Biologics Experts in the Clinic ⛳️🧬✨ What happens when two Ontario derms swap the golf course for the Skin and Joints studio? You get a rapid-fire, real-world deep dive into bimekizumab for plaque psoriasis—complete with candid golf confessions, myth-busting on intra-class switching, and a candidiasis reality check you can actually use. Dr. Ron Vender (80 rounds a season 🙌) and Dr. Jensen Yeung (proud caddy and data devotee) unpack their 16-week, multicentre retrospective review of adults with moderate to severe PsO who’d already tangoed with other IL-17 inhibitors. Spoiler: 86 % hit IGA 0/1 and PASI 90, while 63 % nailed PASI 100. Not bad for so-called “tough” patients. Expect quick-hit pearls on why dual IL-17 A + F blockade matters, how to frame the switch and treatment class conversation in 30 seconds, and why starting with your heaviest hitter first-line might be a good real world strategy️‍♀️💡 🎯 Learning Objectives Decode the Data 📊Translate 16-week real-world outcomes (IGA 0/1, PASI 90/100) into day-to-day decision-making for IL-17–experienced psoriasis patients. Master the Switch 🔄Compare primary vs secondary non-responders—and justify when intra-class IL-17 switching still makes clinical (and payer) sense. Counsel with Confidence 🗣️Craft a 30-60-second convo to prep patients to set realistic skin clearance expectations. Rethink the Ladder 🪜Debate first-line versus “last-resort” positioning the current IL-17 vs IL-23 landscape. Plan for Durability 📅Identify unanswered questions—1-year persistence, multi-failure cohorts—and how ongoing real-world follow-up could reshape treatment algorithms. 🔔 Hit play, level up your treatment playbook, and maybe even shave a few strokes off your psoriasis management game. #SkinAndJointsPodcast #PsoriasisPearls 🩺 EXCLUSIVE TO THE SKIN AND JOINTS PODCAST About Dr. Ron Vender MD, FRCPC Dermatologist | Hamilton Dr. Ron Vender is a Dermatologist who currently practices in Hamilton. He is the founder and director of Dermatrials Research Incorporated and Venderm Innovations in Psoriasis. He has participated as principal investigator in over 100 clinical trials. He is Associate Clinical Professor at McMaster University in the Department of Medicine, Division of Dermatology. Dr. Vender serves on the editorial board of the Journal of Cutaneous Medicine and Surgery reviewer for the JEADV, JAAD, and BJD. He is one of eight Canadians elected to the International Psoriasis Council, a member of the Canadian Professors of Dermatology and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. He represents Canada on several global educational steering committees as well as international advisory boards. He has published over 100 peer-reviewed manuscripts and has had posters, abstracts and lectures presented internationally. About Dr.Jensen Yeung MD, FRCPC Dermatologist | Toronto Dr. Jensen Yeung obtained a B.Sc. (Honours) and MD from McMaster University in 2001. In the same year, he began his dermatology residency training at the University of Toronto. During his residency training, he spent 6 months in Australia, New York, and Boston gaining clinical experience and acquiring the newest knowledge in the field of melanoma and dermoscopy from leading experts. In 2005, he was selected by the residency program as the co-chief resident for the year. Having obtained his board certification from the Royal College of Physicians and Surgeons of Canada in 2006, he joined the Faculty of Dermatology at the University of Toronto, where he ran teaching clinics at both Women’s College Hospital and the Sunnybrook Health Sciences Centre. In 2007, he was promoted to the position of medical director for the RKS Dermatology Program at Women’s College Hospital, where he ran a melanoma, psoriasis, and General Dermatology clinic. In 2013, he switched from RKS to PERC and took on the new role as the medical director of PERC (phototherapy education and research centre) where he runs weekly psoriasis/phototherapy clinic. In 2014, he and Dr. Dana Jerome started a monthly combined psoriasis/psoriatic arthritis clinic at PERC. In 2011, he joined Dr. Kim Papp’s research facility in Waterloo and has participated in over 200 phase 1 to 4 clinical trials. He has also supervised and mentored many research students and residents, which has led to around 180 peer-reviewed publications. He is an associate editor at JCMS and Canadian Dermatology Today. He has received a number of teaching awards including the best resident teacher award in 2005, the 2008 Women’s College Hospital Department of Medicine Postgraduate Teaching Award, the 2009 University of Toronto Dermatology Postgraduate Program Staff Teaching Award, and the 2023 University of Toronto Department of Medicine Award for Excellence in Postgraduate Teaching. 📻www.skinandjoints.ca ✉️info@skinandjoints.ca

🎙️ Skin & Joints Podcast — Acne Aisle Adventure with Dr. Sonya Abdulla (Part 2 of 3) 🎙️ Dr. Sonya Abdulla is back at the mic, and her shopping cart is starting to look like it needs four-wheel drive. This second instalment rockets from benzoyl-peroxide to sulfur’s glow-up (no more rotten-egg vibes), detours into niacinamide’s barrier-boosting superpowers, and lands on why retinol deserves a nightly standing ovation. 🛒💥🧴 Learning Objectives 📚✨ By the end of Part 2, listeners will be able to: 1. Dose & Dispense Like a Pro o Choose between OTC benzoyl-peroxide and retinol strengths that maximize efficacy while minimizing irritation. 🧼 2. Spot-Treat Smarter o Compare sulfur vs. niacinamide vs. hydrocolloid patches for on-demand blemish triage and know when each option is optimally introduced 🔍 3. Master the Mixology o Sequence AM/PM regimens so retinoids and peroxides play nice, and decode proprietary formulas when % labels ghost you. 🕵️‍♀️ 4. Escalate with Confidence o Recognize red-flags that warrant prescription-strength upgrades or derm referral. 🚑 ________________________________________ 🔍 Ingredient Sneak Peek — What’s Rolling onto the Conveyor Belt: • Benzoyl Peroxide: The OG bacteria-slayer • Sulfur: Acne care’s retro revival • Niacinamide: The Swiss-army vitamin • Retinol / Retinaldehyde: Night-shift gene whisperers that keep new breakouts from ever RSVPing. • Hydrocolloid Patches: Tiny panic rooms for pimples Catch the full low-down (percentages, pro hacks, and combo tricks) in the episode—your shopping cart will never be the same. 🎧🛒💥 #AcneAisleMiniSeries #SkinAndJointsPodcast #PharmToDerm 🛍️💡 ABOUT Dr. Sonya Abdulla Dr. Abdulla is a board-certified dermatologist in Canada and the USA and has a blended medical and aesthetic dermatology practice at Dermatology on Bloor in Toronto. She earned her degree from the University of Ottawa, where she was awarded the Dr. André Peloquin Award for excellence in patient care. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto. Dr. Abdulla is an active member of the Canadian Dermatology Association, American Academy of Dermatology, American Society of Dermatologic Surgery, European Academy of Dermatology and Venereology, Ontario Medical Association, and Canadian Medical Association. Additionally, she is a published author with numerous articles in peer-reviewed scientific journals. Made possible with the support of Kenvue Neutrogena #AcneCare #TopicalTreatments #SkincareJourney #Derm #PodcastAlert #SkinAndJoints #innovation

🎙️ Part 2 – Safety First 🛡️✨ Still basking in Orlando sun, the crew zooms from efficacy fireworks to the serious stuff: a massive 2,500-patient-year integrated safety update on abrocitinib. Dr. Loo runs the numbers so you don’t have to: Four-and-a-half years of data, ~1,600 patients, ages 18–39 📊 No signal for VTE, MACE, or new malignancies despite the boxed-warning hype 🚫❤️‍🩹 Main watch-out: shingles (herpes zoster) pops more in adults than teens Dr. Liu’s playbook: Benefit → then risk. The speedy itch-relief first, mention nausea/headache next, finish with Black-Box context (RA ≠ AD, pan vs selective JAK). Vaccinate, don’t vacillate. Shingrix before, during, or after start—flexibility wins. Lab light-touch. CBC, LFTs, creatinine at baseline & month 1, then q6mo. Dose dance. 200 mg for “put-out-the-fire” severe cases; 100 mg for teens, 65+ or comorbidity-heavy adults—with room to escalate. 🎯 Learning Objectives Summarize long-term safety signals of abrocitinib in moderate–severe AD and contrast them with boxed-warning concerns. Apply age- and risk-stratified dosing in shared decision-making for JAK initiation or escalation. #SkinAndJointsPodcast #AAD2025 #JAKSafety #Abrocitinib #EczemaCare #DermEd #ItchRelief #MedTwitter 🎧 About Dr Wei Jing Loo, BSc (Med), MBBS, MRCP (UK), FRCP(c) Dermatologist | London, ON Dr Wei Jing Loo is the owner and Medical Director of DermEffects, a cutting edge dermatology centre located in London, Ontario. Dr Loo completed medical school in 1997 with an honours degree from the University of New South Wales in Sydney, Australia. She trained in Internal Medicine and obtained membership in the Royal College of Physicians in the United Kingdom in 1999. She completed her dermatology residency training in Cambridge, United Kingdom and obtained her Certificate of Specialist Training in Dermatology in 2005. She is board certified in Canada and a fellow of the Royal College of Physicians and Surgeons of Canada. She is a member of the Canadian Dermatology Association and American Academy of Dermatology. Dr. Loo is at the forefront of the dynamic field of dermatology, serving as an associate investigator for Probity Medical Research. Dr. Loo is an Adjunct Professor at Western University in Ontario. She enjoys teaching and has published her work in many peer-reviewed journals

Episode: Do I start at 15 or jump straight to 30? Key Questions Answered: What’s the translational takeaway for dermatologists?🩺 Do these findings reassure you about dose escalation or reduction?🤔 15 mg vs. 30 mg-clinic conundrum solved🏷️ 🌴☀️ Sunshine, palm trees, and late-breaking dermatology data! 🎙️💡 In this special live episode of the Skin and Joints Podcast, from the AAD 2025 in sunny Orlando, Florida, we breakdown the FLEX UP late breaking trial results for upadacitinib for moderate to severe atopic dermatitis with with two leading Canadian dermatologists: Dr. Melinda Gooderham and Dr. Angela Law! They also share their ultimate “conference flexes” We go beyond EASI, spotlighting itch control 🤲, quality of life, and real-world relevance 🏥 for all those asking, “So what does this mean practically? Together, our experts explore how this flexible dosing study answers a longstanding question: Should you start patients on the 15 mg or 30 mg dose, and can you switch between them for better results? Hear how this late-breaking data might recalibrate your go-to prescribing assessment and whether it’s time to tweak your approach. The discussion pokes at the trial’s design, why Week 12 and 24 were selected, the importance of itch reduction, and safety data. Dr. Gooderham and Dr. Law also weigh in on how these findings might—or might not—revolutionize current clinical practice. Learning Objectives FLEX UP Trial Design & Rationale Grasp how the study was structured to evaluate flexible dosing of upadacitinib at 15 mg and 30 mg. Clinical Efficacy Measures Understand the role of EASI 90, NRS, and quality-of-life metrics in gauging patient outcomes. Real-World Implications Examine how FLEX UP data supports practical dosing choices—starting big or small—and equips you to address patient questions about switching doses. Safety & Tolerability Summarize the key safety findings (including VTE, serious infections, and zoster) and how they align with existing JAK-inhibitor data. Future Directions Recognize the need for longer-term follow-up and additional analyses to further refine flexible dosing strategies and patient selection. 🌞 Grab a comfy pair of sneakers 👟 and a protein bar 🍫 because we’re tackling front-line, day-to-day dilemmas in AD management—once and for all! Expect wit, warmth, and wisdom in this fast-paced chat, complete with palm trees, protein bars, and plenty of pro tips. ABOUT DR. MELINDA GOODERHAM Dermatologist, Peterborough, ON Dr. Melinda Gooderham is a well-established dermatologist who serves as medical director at the SKiN Centre for Dermatology and the principal investigator for the SKiN Research Centre. Dr. Gooderham received her MD from the University of Western Ontario in 1999 and then completed her Dermatology residency at the University of Toronto in 2004. Before training in medicine, Dr. Gooderham obtained a Bachelor of Science degree from Queen’s University in Kingston in 1992 and a Master of Science degree from the University of Guelph in 1995. Dr. Gooderham is an Assistant Professor at Queens University and works as a Consultant Physician at the Peterborough Regional Health Centre (PRHC). A fellow of the Royal College of Physicians and Surgeons of Canada, she has investigated over 200 clinical trials focusing on inflammatory skin diseases, including psoriasis and atopic dermatitis. Beyond clinical practice, Dr. Gooderham actively contributes to dermatology publications as an author, reviewer, and associate editor, with authorship of over 200 articles. Her passion for education extends to global audiences through engaging lectures on innovative therapies for skin diseases. About DR. ANGELA LAW MD, FRCPC Dermatologist | VANCOUVER, BC Dr. Angela Law is a board certified Dermatologist in both Canada and the United States. She completed her dermatology residency in a joint program at the University of Saskatchewan and Dalhousie University. She is a Clinical Instructor in the Department of Dermatology and Skin Science at UBC, regularly teaching medical students and residents, and runs the Urgent Dermatology Clinic at Mount Saint Joseph’s Hospital. She also has an active dermatology practice in downtown Vancouver. Dr. Law also runs the Vulvar Dermatology Clinic at Mount Saint Joseph’s Hospital which is an innovative clinic with a focus on Women’s Health within Providence Health Care. Episode supported by Abbvie.

Lights, laughter, and lasers on sebum?! 🤔 Absolutely! Join us for our first-ever Skin and Joints Podcast episode live at Fall Clinical 2024 in sunny Las Vegas. 🎰 We’re unveiling our new segment “Cross-Border Talk,” featuring Dr. Zoe Diana Dreyloos (reformed mechanical engineer ✈️ from North Carolina) and Dr. Andrei Medlitsa US-based dermatologist (hello, North Carolina!) and a Canadian colleague (brrr, Calgary!) trade professional pearls and unique perspectives on acne care. Expect runway-ready insights on: The big reveal of Clascoterone cream’s impact on sebum production (yep, they used a “sebum meter!”) Brand-new data showing significant improvements in both inflammatory and non-inflammatory acne lesions The “golden ticket” to fine dining in Vegas, plus confessions of flight fantasies (hint: not all high-flying action happens at the blackjack table) If you’re tired of your patients asking, “Doc, how do I zap this shine?”—this is the episode for you. Because (despite the famous saying) what happens in Vegas definitely won’t stay in Vegas this time. Tune in for the scoop on everything from sebum science to top-secret bunker restaurants. 🍸 Episode Learning Objectives Understand the central role of sebum production in acne pathogenesis and how it shapes therapeutic strategies. Evaluate the newly released 12-week clinical data on Clascoterone cream 1%—with measured impact on both inflammatory and non-inflammatory lesions. Discuss the safety and tolerability profile of Clascoterone, including real-world patient adherence considerations. Translate the study’s findings into everyday practice, identifying which acne patients might benefit most from sebum-targeted therapy. Explore future research directions, including combination approaches, longer-term outcomes, and potential applications in severe acne or pore-size reduction. Understand the pivotal role of sebum production in acne pathogenesis and how it shapes therapeutic decisions. Examine the newest 12-week clinical data on Clascoterone cream 1%—including its documented impact on both inflammatory and non-inflammatory acne lesions. Apply practical tips for integrating Clascoterone into real-world regimens, tackling oily skin head-on with confidence. Get ready to rethink your acne game plan… Get ready for an antioxidant masterclass 🤓✨— that’ll have you completely rethinking your recommendations! ABOUT Dr. Zoe Diana Draelos, MD, FAAD DERMATOLOGIST, HIGH POINT, NORTH CAROLINA Zoe Diana Draelos, MD, is a research and clinical board-certified dermatologist and a Fellow of the American Academy of Dermatology. She is in solo private practice in High Point, North Carolina, and a Consulting Professor of Dermatology at Duke University. In 1988, she founded Dermatology Consulting Services, PLLC, to initiate and perform research in aging skin, acne, rosacea, psoriasis, atopic dermatitis, actinic keratoses, eczema, and aesthetic procedures in the cosmetic, OTC drug, and pharmaceutical arenas. Prior to pursuing a medical career, Dr. Draelos completed an undergraduate degree in Mechanical Engineering and was elected a Rhodes Scholar. A member of Sigma Xi research honorary and Alpha Omega Alpha medical honorary, she is author of 14 books including Cosmetics in Dermatology and Hair Cosmetics. She is the editor of Cosmetic Dermatology: Products and Procedures (third edition) and Cosmeceuticals (fourth edition) with translations into 7 languages. She has contributed chapters to 44 textbooks, written 173 posters, served as the principal investigator on 982 studies, written 650 published papers, served on or contributed to 38 journal editorial boards, functioned as the editor-in-chief of the Journal of Cosmetic Dermatology for 10 years, and was a past member of the Board of Directors of the American Academy of Dermatology and the American Society for Dermatologic Surgery. She was elected Vice-President of the American Academy of Dermatology. She is recognized as a pioneer in cosmetic dermatology and received a lifetime achievement award from Health Beauty America for her research and the 2008 DermArts award for her contributions to dermatology. In 2010, she received the Albert Kligman Innovation Award and in 2016 she was awarded a Presidential Citation from the American Academy of Dermatology for her research contributions to advance the specialty. She received the prestigious Maison deNavarre award from the Society of Cosmetic Chemists for her contributions to the art and science of cosmetics in 2017. In 2019, she was the inaugural recipient of the Florence Wall Award from the Society of Cosmetics Chemists naming her as the most influential women in cosmetic science. ABOUT Dr. Andrei Metelitsa, MD, FRCPC, FAAD DERMATOLOGIST, CALGARY, AB Dr. Metelitsa is a Board-Certified Dermatologist in both Canada and United States and is currently a Clinical Professor at the University of Calgary's Faculty of Medicine. He graduated from medical school at the University of Alberta, Canada at the age of 23. He further received a 5-year dermatology training at the University of Alberta. After completing his residency, Dr. Metelitsa pursued an additional 1-year fellowship training in Lasers and Cosmetic Surgery in Boston, Massachusetts at SkinCare Physicians under the direction of world-renowned faculty from Harvard and Yale. Dr Metelitsa’s Special Interests include: Botox and Dysport injections, Restylane and Juvederm Injections (filler), CO2 Laser Rejuvenation, Excel V Laser, Skin Cancer, Psoriasis. Dr. Metelitsa is also a primary investigator for clinical trial for new and novel dermatology conditions at Beacon Dermatology. SUPPORTED BY SUN PHARMA ABOUT DR.MARK LUPIN MD FRCPC DABD VICTORIA, BC Dr. Lupin is a Board-certified Dermatologist, Founder in 1998 of Cosmedica Laser Centre in Victoria, British Columbia and Chief Clinical Officer of MedSpa Partners Inc.He has degrees in Mathematics, Music and Medicine having studied at the University of Toronto, University of British Columbia, Dalhousie University, Indiana University and the University of Southern California. He has special interests in photodermatology and laser medicine, having studied under Professor John Hawk at St John’s Institute of Dermatology, London, England. He is active with research and education, has additional subspecialty training in Neurology and is past President of the Canadian Laser Aesthetic Surgery Society. As a concert violinist, Dr Lupin has performed as soloist at Carnegie Hall, New York and with major orchestras around the world. He is Concertmaster of the World Doctors Orchestra (WDO), performing most recently in Australia at the Sydney Opera House, with all proceeds donated to charities. His research interests extend to space medicine and fluid dynamics where he has been active with mathematical modeling for space tools and has developed several patent pending energy efficient devices. ABOUT Dr. Vincent Richer MD FRCPC VANCOUVER, BC Dr Vincent Richer practices cosmetic dermatology at Pacific Derm Atelier in Vancouver and holds a position as Clinical Assistant Professor at the University of British Columbia’s Department of Dermatology and Skin Science. He trained at Université de Montréal in Medicine and Dermatology and completed a fellowship in Photobiology and Cutaneous Laser Surgery at UBC. He is involved as a subinvestigator in cosmetic clinical trials, has published 35+ peer reviewed scientific articles and is active in undergraduate, graduate and continuing medical education. EPISODE SUPPORTED BY SKINCEUTICALS AND SKINBETTER SCIENCE. 📻www.skinandjoints.ca ✉️info@skinandjoints.ca

Unlocking the Secrets of Clear Skin (and Soggy Shoes) in Amsterdam! 🌧️👟✨ Ready to revolutionize your approach to atopic dermatitis? 🤔 Join us on the latest episode of the Skin and Joints podcast, live from the EADV in Amsterdam! 🇳🇱 Dr. Marissa Joseph and Dr. Max Sauder, braved the Dutch downpours to bring you exclusive insights into lebrikizumab—the new kid on the block that's making waves 🌊 in eczema treatment. Discover how this IL-13 inhibitor is changing the game 🎯 with its long-term efficacy, flexible dosing schedules, and impressive safety profile. 📊 We'll dive deep into the ADJOIN study's three-year data, discuss where lebrikizumab fits into the current treatment landscape for their respective practices 🩺, and explore how it could be a game-changer for your patients. 🧑‍⚕️👩‍⚕️ 🗺️Get a taste of our guests' Amsterdam adventures—from waterlogged wanderings 🚶‍♀️🌧️ to culinary delights at Nomads restaurant. 🍽️ Plus, find out why Max might be shopping for a princess dress 👗 before the next conference 🏰🎢 🎙️ Tune in and get ready to see atopic dermatitis treatment in a whole new light! 💡 Learning Objectives: Understand the mechanism of action of lebrikizumab in treating atopic dermatitis, focusing on its role as an IL-13 inhibitor 🧬. Analyze the long-term efficacy and safety data from the ADjoin study, emphasizing the durability of lebrikizumab over a three-year period 📈. Compare the dosing regimens (biweekly vs. monthly) of lebrikizumab and their implications for patient adherence and treatment outcomes 📆. Evaluate how lebrikizumab fits into current clinical practice for atopic dermatitis, considering patient preferences and the spectrum of available therapies 🩺. Recognize the importance of expanding therapeutic options in atopic dermatitis management and how to personalized patient care 🎯. ABOUT DR.MARISSA JOSEPH Dermatologist, Toronto, ON Marissa Joseph, MSc, MD, FRCPC ( Pediatrics), FRCPC ( Dermatology) Dr. Marissa Joseph is a board certified Pediatrician and Dermatologist after completing Pediatric training at the Hospital For Sick Children, following with a Dermatology residency at the University of Toronto. She completed a MSc in Community Health at the Dalla Lana School of Public Health. Dr. Joseph is full time academic faculty at the Unee Schachter Dermatology Centre at Women's College Hospital. She also works at the Hospital For Sick Children where she manages children with complex dermatologic disease in outpatient and inpatient settings, as well as a pediatric laser treatment program. Dr. Joseph enjoys her diverse practice in general adult, pediatric and surgical dermatology. Her clinical and research interests include inflammatory skin disorders such as psoriasis, atopic dermatitis, and hidradenitis suppurativersity of Toronto. She has received and has been nominated for teaching awards in both undergraduate and postgraduate medical education. Dr. Joseph is the Medical Director of the Ricky Kaniva; genodermatoses, and equity, diversity and inclusivity. About Dr.Maxwell Sauder MD, FRCPC Dermatologist | Toronto Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School. Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic. Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions. 🚴 📻www.skinandjoints.ca ✉️info@skinandjoints.ca

🎙 Amsterdam Stories, Delta Force & A Game-Changing Topical for Chronic Hand Eczema 🎉✨ Melinda Knows Best is BACK! 🚀💥 This time, Dr. Gooderham brings us a heavyweight showdown 🥊 between a new topical superhero 🦸‍♀️ and the reigning oral champ 💊 in the battle against Chronic Hand Eczema! reporting live from the European Academy of Dermatology and Venereology (EADV) Congress in the beautiful city of Amsterdam! 🇳🇱✨ In this special episode, we’re diving into the Delta Force Trial – a bold study comparing topical delgocitinib to oral alitretinoin for chronic hand eczema 💊🧴 👀 Dr. Gooderham spills the beans on impressive results, rapid relief, and how this new treatment is about to change the game for dermatologists and patients alike. 🎉 Oh, and don’t worry, we didn’t forget to ask about her Amsterdam adventures! 🌍 Did she run into some famous faces at dinner? 🍽️👀 Tune in for the scoop! 💡 Melinda Knows Best will keep you at the cutting edge of CHE breakthroughs. 👩‍⚕️✨ 🎯 Learning Objectives: Explore the Delta Force Trial Findings: Understand the significance of the Delta Force trial comparing topical delgocitinib to oral alitretinoin for chronic hand eczema. 🧴💊 Evaluate the Efficacy of Topicals vs Orals for chronic hand eczema: Learn about the early onset of symptom relief with delgocitinib, including i reductions in HEXI scores and patient quality of life improvements. ⏱️📉 Identify Key Real-World Implications: Discuss how this new topical treatment can shift the landscape for clinicians and patients, offering rapid, safe relief without the headaches (literally!) of oral therapies. 💡 Dive into secondary endpoints, including itch and pain relief, and how this data compares to other major clinical trials in hand eczema treatment. 📊🔬 ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology) Toronto, ON Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases. 📻www.skinandjoints.ca ✉️info@skinandjoints.ca

🎙️ More than Skin Deep Insights with Dr. Lauren Lam!🎙️ 👩‍⚕️💬 As we get close to wrapping up our coverage of AAD 2024, get ready as we welcome back Dr. Lauren Lam. We dive deep into her recent experience at the AAD in sunny San Diego. 🌞🏖️ Learning Objectives: 🧠 Understand the practical applications of translational medicine in dermatology, particularly in treating chronic skin conditions. 🛠️ Identify key clinical pearls and advancements in dermatology that can be immediately implemented in practice to improve patient care. What’s on the agenda for this mini-podcast drop? 🌟 San Diego Stories: From bar hopping in a Japanese-themed spot 🌸🍹 to pelican watching at the pier 🦩📸, Lauren shares her unique experiences and the vibrant cultural mix that San Diego offers. 🔍 Translational Medicine Takeaways: Discover how the latest advancements in bench-to-bedside research are transforming dermatological practices. 🧬🩺 💡 Clinical Pearls Galore: Hidradenitis Suppurativa Insights: Understand why de-roofing is essential even with biologics 🩹🔬. Alopecia Areata Breakthroughs: Learn about the impact of JAK inhibitors 🧑‍🦲➡️🧑‍🦰. Pyoderma Gangrenosum Progress: Hear about the promising results of IL-36 inhibitors in treating this challenging condition 💉🌟. Join us for a lively episode that blends professional insights with personal anecdotes, and don't miss out on the laughter and wisdom Dr. Lam brings to the table 🎧✨ ABOUT Dr. Lauren Lam Dermatologist | Calgary Dr. Lauren Lam is a Canadian & American board-certified dermatologist. She is a native Calgarian who completed her medical school training at the University of Calgary & her dermatology residency at the University of Alberta. Since graduating, Dr. Lam has become a Clinical Lecturer with the University of Alberta. Her particular passions in dermatology are acne & hidradenitis suppurativa deroofings. In addition to her regular practice, she volunteers on overseas medical trips. Her passion for providing care for under-served populations has taken her to Nunavut & rural Fiji. Outside of medicine, Dr. Lam is a proud aunt to 4 dogs, culinary enthusiast & international explorer.

🌞🎧Dermatologist Dr.Max Sauder joins us back on the podcast and navigates us through the complexities of modern dermatological care💡 🎙️ My CASMO (Canadian Skin Management in Oncology) Playbook: Part 1 🎙️ Get ready for a laugh and learn session as Dr. Jessica Asgarpour takes the co-hosting hot seat! This episode, we’re diving headfirst into the CASMO project with dermo-oncologist Dr. Max Sauder. We’ll decode the CASMO algorithm, tackle the nitty-gritty of managing skin toxicities, and even uncover Dr. Sauder's secret summer plans. Buckle up! 🎢 Episode Description: We're peeling back the layers of the CASMO project, an innovative approach to managing skin toxicities in cancer treatment. Can certain skin toxicities be prevented in patients? Is there a proactive skincare regimen that can be recommended for patients? 1. Introduction to CaSMO and Skin Toxicities in Cancer Treatment: Overview of the significance of managing skin toxicities, introducing the CaSMO algorithm's development and objectives. 2. Prevention Strategies: Detailed discussion on general skincare measures recommended by CaSMO, including the rationale behind the use of cleansers and moisturizers to maintain skin hydration and integrity. Episode Learning Objectives: 1. Understand the CASMO algorithm and its role in managing skin toxicities associated with cancer treatments. 2. Recognize the importance of a multidisciplinary approach in improving patient outcomes. 3. Identify practical proactive strategies for preventing and managing skin toxicities. 4. Learn about the impact of skin toxicities on patients' quality of life and how to address these issues. 5. Explore the role of various healthcare providers, including oncologists, nurses, and pharmacists, in supporting patients through their cancer journey. Press play for a dose of dermatological delight 🎙️✨ Episode supported by an IME Grant from LA ROCHE POSAY About Dr.Maxwell Sauder MD, FRCPC Dermatologist | Toronto Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School. Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic. Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions. 📻www.skinandjoints.ca ✉️info@skinandjoints.ca